| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| April 7, 2026 | ±2.5% | -0.8% | over-priced |
| January 7, 2026 | ±1.7% | -0.4% | over-priced |
| October 8, 2025 | ±1.4% | -0.2% | over-priced |
| April 3, 2025 | ±2.0% | -1.8% | over-priced |
| January 8, 2025 | ±2.2% | +2.1% | over-priced |
| October 4, 2024 | ±1.8% | +0.2% | over-priced |
| April 5, 2024 | ±1.8% | +1.4% | over-priced |
| January 8, 2024 | ±1.8% | +1.2% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q3 FY2026 | $1.24 | $2.8B | $502M |
| Q2 FY2026 | $1.21 | $2.8B | $495M |
| Q1 FY2026 | $1.20 | $2.7B | $491M |
| Q4 FY2025 | $1.09 | $2.7B | $448M |
Cintas Corp (CTAS) reports in 46 days, with the next report estimated for July 29, 2026. Across the last 8 reports, options priced an average ±1.9% earnings move while the stock actually moved 1.0% on average — the market has systematically over-priced CTAS's earnings risk. Fundamentals into the print: EPS up 9.7% year-over-year, revenue up 8.9%. QuantLogix's live 5-factor engine currently reads CTAS as a buy at 52/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →